SCHEMBL5090091

SCHEMBL5090091

CN1CC2C[C@]2(c2cccc3ccccc23)C1

nearest known ligand 0.70

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 7/20 0.70
SLC6A4 P31645 7/20 0.70
SLC6A3 Q01959 7/20 0.70
CYP2D6 P10635 4/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4181300 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL16213934 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL4194655 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL13698167 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL16214795 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL4185801 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
SCHEMBL31284725 1.00 SLC6A2 (0.70) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
Hydrochloric Acid SCHEMBL4187651 0.98 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
Hydrochloric Acid SCHEMBL4191444 0.98 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E
Hydrochloric Acid SCHEMBL4188232 0.98 SLC6A2 (0.68) SLC6A2SLC6A4SLC6A3CYP2D6KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915146-A2 NOVEL 1-ARYL-3-AZABICYCLOÝ3.1.0¨HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS DOV Pharmaceutical, Inc. (US) 2008-04-30 EP claimed
WO-2007016155-A2 NOVEL 1-ARYL-3-AZABICYCLO[3.1.0]HEXANES: PREPARATION AND USE TO TREAT NEUROPSYCHIATRIC DISORDERS DOV PHARMACEUTICAL, INC. (US) 2007-02-08 WO claimed